GREAT POINT PARTNERS LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
165 Mason Street, 3rd Floor Greenwich, CT 06830
As of the latest 13F report, the guru’s equity portfolio contained 42 stocks valued at a total of $510.00Mil. The top holdings were PCVX(7.52%), XENE(6.57%), and RAPT(5.58%).
According to GuruFocus data, these were GREAT POINT PARTNERS LLC’s top five trades of the quarter.
Avalo Therapeutics Inc
The guru established a new position worth 974,639 shares in NAS:AVTX, giving the stock a 0.9% weight in the equity portfolio. Shares traded for an average price of $3.89 during the quarter.
On 02/18/2023, Avalo Therapeutics Inc traded for a price of $3.11 per share and a market cap of $41.00Mil. The stock has returned -68.60% over the past year.
GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Avalo Therapeutics Inc has a EV-to-Ebitda ratio of -0.90 and a price-sales ratio of 1.66.
The price-to-GF Value ratio is 0.08, earning the stock a GF Value rank of 2.
Relmada Therapeutics Inc
The guru sold out of their 510,000-share investment in NAS:RLMD. Previously, the stock had a 4.55% weight in the equity portfolio. Shares traded for an average price of $8.779999999999999 during the quarter.
On 02/18/2023, Relmada Therapeutics Inc traded for a price of $3.67 per share and a market cap of $110.46Mil. The stock has returned -80.36% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Relmada Therapeutics Inc has a price-book ratio of 0.63 and a EV-to-Ebitda ratio of 0.49.
RAPT Therapeutics Inc
During the quarter, GREAT POINT PARTNERS LLC bought 1,121,569 shares of NAS:RAPT for a total holding of 1,436,569. The trade had a 4.36% impact on the equity portfolio. During the quarter, the stock traded for an average price of $20.01.
On 02/18/2023, RAPT Therapeutics Inc traded for a price of $29.58 per share and a market cap of $1.00Bil. The stock has returned 43.38% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, RAPT Therapeutics Inc has a price-book ratio of 4.67, a EV-to-Ebitda ratio of -9.59 and a price-sales ratio of 393.83.
The price-to-GF Value ratio is 3.74, earning the stock a GF Value rank of 1.
IVERIC bio Inc
The guru established a new position worth 825,000 shares in NAS:ISEE, giving the stock a 3.46% weight in the equity portfolio. Shares traded for an average price of $21.34 during the quarter.
On 02/18/2023, IVERIC bio Inc traded for a price of $21.95 per share and a market cap of $2.94Bil. The stock has returned 48.81% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, IVERIC bio Inc has a price-book ratio of 10.21 and a EV-to-Ebitda ratio of -15.07.
Galapagos NV
The guru sold out of their 306,411-share investment in NAS:GLPG. Previously, the stock had a 3.15% weight in the equity portfolio. Shares traded for an average price of $42.08 during the quarter.
On 02/18/2023, Galapagos NV traded for a price of $39.43 per share and a market cap of $2.60Bil. The stock has returned -41.06% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 4 out of 10.
In terms of valuation, Galapagos NV has a price-earnings ratio of 480.85, a price-book ratio of 0.90, a EV-to-Ebitda ratio of -29.94 and a price-sales ratio of 4.15.
The price-to-GF Value ratio is 0.56, earning the stock a GF Value rank of 8.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
